Literature DB >> 8662974

Transcriptional regulation of the human biglycan gene.

H Ungefroren1, N B Krull.   

Abstract

The small leucine-rich proteoglycan biglycan is involved in several physiological and pathophysiological processes through the ability of its core protein to interact with other extracellular matrix molecules and transforming growth factor-beta (TGF-beta). To learn more about the regulation of biglycan core protein expression, we have cloned and sequenced 1218 base pairs from the 5'-flanking region of the human biglycan gene, demonstrated functional promoter activity, and investigated the molecular mechanisms through which various agents modulate its transcriptional activity. Sequencing revealed the presence of several cis-acting elements including multiple AP-2 sites and interleukin-6 response elements, a NF-kappaB site, a TGF-beta negative element, and an E-box. The TATA and CAAT box-lacking promoter possesses many features of a growth-related gene, e.g. a GC-rich immediate 5' region, many Sp1 sites, and the use of multiple transcriptional start sites. Transient transfections of the tumor cell lines MG-63, SK-UT-1, and T47D with various biglycan 5'-flanking region-luciferase reporter gene constructs showed that the proximal 78 base pairs are sufficient for full promoter activity. Several agents among them interleukin-6, and tumor necrosis factor-alpha. were capable of altering biglycan promoter activity. However, in MG-63 cells, TGF-beta1 failed to increase either activity of the biglycan promoter constructs or specific transcription from the endogenous biglycan gene. Since TGF-beta1 also did not alter the stability of cytoplasmic biglycan mRNA as determined from Northern analysis after inhibition of transcription with 5,6-dichloro-1beta-D-ribofuranosylbenzimidazole, an as yet unidentified nuclear post-transcriptional mechanism was considered responsible for the TGF-beta effect in this cell type. These results might help to elucidate the molecular pathways leading to pathological alterations of biglycan expression observed in atherosclerosis, glomerulonephritis, and fibrosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662974     DOI: 10.1074/jbc.271.26.15787

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Proteoglycan expression during transforming growth factor beta -induced keratocyte-myofibroblast transdifferentiation.

Authors:  J L Funderburgh; M L Funderburgh; M M Mann; L Corpuz; M R Roth
Journal:  J Biol Chem       Date:  2001-09-12       Impact factor: 5.157

2.  Modulation of sulfated glycosaminoglycan and small proteoglycan synthesis by the extracellular matrix.

Authors:  Y Wegrowski; P Gillery; G Kotlarz; C Perreau; N Georges; F X Maquart
Journal:  Mol Cell Biochem       Date:  2000-02       Impact factor: 3.396

3.  ADAMTS-4 and biglycan are expressed at high levels and co-localize to podosomes during endothelial cell tubulogenesis in vitro.

Authors:  Masanari Obika; Robert B Vernon; Michel D Gooden; Kathleen R Braun; Christina K Chan; Thomas N Wight
Journal:  J Histochem Cytochem       Date:  2013-09-18       Impact factor: 2.479

4.  The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis.

Authors:  Kristin Moreth; Rebekka Brodbeck; Andrea Babelova; Norbert Gretz; Tilmann Spieker; Jinyang Zeng-Brouwers; Josef Pfeilschifter; Marian F Young; Roland M Schaefer; Liliana Schaefer
Journal:  J Clin Invest       Date:  2010-11-15       Impact factor: 14.808

5.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages.

Authors:  Liliana Schaefer; Andrea Babelova; Eva Kiss; Heinz-J Hausser; Martina Baliova; Miroslava Krzyzankova; Gunther Marsche; Marian F Young; Daniel Mihalik; Martin Götte; Ernst Malle; Roland M Schaefer; Hermann-Josef Gröne
Journal:  J Clin Invest       Date:  2005-07-14       Impact factor: 14.808

Review 6.  Biglycan knockout mice: new models for musculoskeletal diseases.

Authors:  Marian F Young; Yanming Bi; Laurent Ameye; Xiao-Dong Chen
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

7.  Characterization of the human proline/arginine-rich end leucine-rich repeat protein (PRELP) gene promoter and identification of a repressor element.

Authors:  J Grover; P J Roughley
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

8.  Diabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis.

Authors:  Thomas O McDonald; Ross G Gerrity; Christy Jen; Hao-Ji Chen; Kathleen Wark; Thomas N Wight; Alan Chait; Kevin D O'Brien
Journal:  J Histochem Cytochem       Date:  2007-07-24       Impact factor: 2.479

9.  Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma.

Authors:  Henry F Frierson; Adel K El-Naggar; John B Welsh; Lisa M Sapinoso; Andrew I Su; Jun Cheng; Takashi Saku; Christopher A Moskaluk; Garret M Hampton
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

10.  Coordinated patterns of gene expressions for adult muscle build-up in transgenic mice expressing myostatin propeptide.

Authors:  Baoping Zhao; Eileena J Li; Robert J Wall; Jinzeng Yang
Journal:  BMC Genomics       Date:  2009-07-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.